ChargePoint Technology report huge surge in China sales as eastern ambitions to overtake US pharma grow
ChargePoint Technology have announced 150 per cent growth (£300k) in new equipment sales in Asia driven by China’s ambitions to become a major player in global pharma.
The company reported the huge surge for the first quarter of 2016 and credited the success of their revolutionary AseptiSafe and high containment PharmaSafe Pro valves for a 386 per cent (£175k) increase in sales in China alone.
ChargePoint Technology already supplies precision containment valves to some of the biggest pharmaceutical names across the globe for the development of medicines and vaccines from their premises in Speke which is home to the largest cluster of biologic manufacturing in Europe.
The AseptiSafe valve creates a sterile area the size of a dinner plate and reduces the need for the large scale clean rooms and isolators to keep drug manufacturing areas sterile. The device also speeds up production, protects operators from hazardous products and keeps raw materials free from bacterial contamination with a unique approach. ChargePoint Technology are the only company which uses a patented hydrogen peroxide decontamination cycle in their valve to destroy contaminants and bacteria, which makes it the most efficient bio-decontamination valve in history.
The Chinese pharma industry has made containment transfer of chemicals used for manufacturing vaccines and powder drugs a priority to comply with the US Food and Drug Administration’s (FDA) strict health and safety rules. By adhering to American standards, it is predicted the Chinese will become the main manufacturer of pharmaceuticals sold in the west.
Tony O’Sullivan, ChargePoint's Global Sales and Marketing Director, said:
“China has woken up to the containment market and is now using more valves for transfers of potent materials, rather than just sterile transfers for vaccine manufacturing.
“We’ve been working for many years in Asia educating the region about containment of hazardous ingredients and they have realised its value.The growth in Asia could mean that one day the East will match the West, where the US and Europe are currently the biggest single marketplaces for sales our containment transfer devices."
“We have also opened new sales channels in South America and further parts of Europe and are reaping the rewards from building our network of agents across the world.
“Our profile has been boosted, particularly in the US, by our attendance at Interphex in New York, which is the world’s largest expo for bio-pharma technology.”
ChargePoint Technology also reported a significant 113 per cent rise (£1m) in sales across their global territories including North America, Europe and India.
Japan and Singapore are continuing to expand on their pharma and bio pharma facilities and there has been an overall growth of 163 per cent (£155k) in the first quarter of 2016.
In India alone sales have rocketed 1,000 per cent (£426k) in the first quarter of 2016 for both their AseptiSafe and PhramaSafe range, with the country’s pharma manufacturers having similar aims to China’s in competing against the west.
Mr O’Sullivan added:
“After an excellent 2015, we are very happy with the results for the start of this year and as ChargePoint’s position in the world of global pharma continues to strengthen, we are confident we will build on our success for the rest of the year.”